Evidence for the existence of the PAF acetylhydrolase mutation (Va1279Phe) in non-Japanese populations: A preliminary study in Turkey, Azerbaijan, and Kyrgyzstan

被引:22
作者
Balta, G [1 ]
Gurgey, A
Kudayarov, DK
Tunc, B
Altay, C
机构
[1] Hacettepe Univ, Fac Med, Dept Pediat, Pediat Hematol Unit, TR-06100 Ankara, Turkey
[2] Inst Obstet & Pediat, Bishkek, Kyrgyzstan
[3] Suleyman Demirel Univ, Fac Med, Pediat Hematol Unit, Isparta, Turkey
关键词
PAF acetylhydrolase; missense mutation; Turkey; Azerbaijan; Kyrgyzstan; population screening;
D O I
10.1016/S0049-3848(00)00394-7
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Deficiency of plasma platelet-activating factor (PAF) acetylhydrolase resulting from a missense mutation (Va1279Phe) in exon 9 of the gene has been described exclusively in the Japanese population with a very high frequency. This study describes the distribution of the mutation in Turkey and two other Turkic nations, Kyrgyzstan in central Asia and Azerbaijan bordering the Caspian Sea. Among 358 unrelated healthy subjects studied from Turkish population, only 3 had the mutation in heterozygous state (0.84%). Family studies also revealed the presence of homozygous individuals in close relatives of one of these subjects. Among 143 healthy subjects studied from Kyrgyzstan, 12 were heterozygous for the mutation (8.4%). No mutation was detected among 100 healthy individuals studied from Azerbaijan. However, it was suggested that the number of subjects was not enough to draw any conclusion about the prevalence of the mutation in the populations studied. Contrary to the previous notions, identification of the mutation in Turkey and Kyrgyzstan shows the existence of the mutation in non-Japanese populations as well. (C) 2001 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:231 / 234
页数:4
相关论文
共 11 条
[1]  
BLANK ML, 1981, J BIOL CHEM, V256, P175
[2]   PLASMA DEGRADATION OF PLATELET-ACTIVATING-FACTOR IN SEVERELY ILL PATIENTS WITH CLINICAL SEPSIS [J].
GRAHAM, RM ;
STEPHENS, CJ ;
SILVESTER, W ;
LEONG, LLL ;
STURM, MJ ;
TAYLOR, RR .
CRITICAL CARE MEDICINE, 1994, 22 (02) :204-212
[3]   A mutation in plasma platelet-activating factor acetylhydrolase (Val(279)->Phe) is a genetic risk factor for stroke [J].
Hiramoto, M ;
Yoshida, H ;
Imaizumi, T ;
Yoshimizu, N ;
Satoh, K .
STROKE, 1997, 28 (12) :2417-2420
[4]   PLATELET-ACTIVATING-FACTOR - A MEDIATOR FOR CLINICIAN [J].
IMAIZUMI, TA ;
STAFFORINI, DM ;
YAMADA, Y ;
MCINTYRE, TM ;
PRESCOTT, SM ;
ZIMMERMAN, GA .
JOURNAL OF INTERNAL MEDICINE, 1995, 238 (01) :5-20
[5]   Deficiency of platelet-activating factor acetylhydrolase is a severity factor for asthma [J].
Stafforini, DM ;
Numao, T ;
Tsodikov, A ;
Vaitkus, D ;
Fukuda, T ;
Watanabe, N ;
Fueki, N ;
McIntyre, TM ;
Zimmerman, GA ;
Makino, S ;
Prescott, SM .
JOURNAL OF CLINICAL INVESTIGATION, 1999, 103 (07) :989-997
[6]   Platelet-activating factor acetylhydrolase deficiency - A missense mutation near the active site of an anti-inflammatory phospholipase [J].
Stafforini, DM ;
Satoh, K ;
Atkinson, DL ;
Tjoelker, LW ;
Eberhardt, C ;
Yoshida, H ;
Imaizumi, T ;
Takamatsu, S ;
Zimmerman, GA ;
McIntyre, TM ;
Gray, PW ;
Prescott, SM .
JOURNAL OF CLINICAL INVESTIGATION, 1996, 97 (12) :2784-2791
[7]   VARIATION IN PLASMA PLATELET-ACTIVATING-FACTOR DEGRADATION AND SERUM-LIPIDS AFTER ACUTE MYOCARDIAL-INFARCTION [J].
STEPHENS, CJ ;
GRAHAM, RM ;
STURM, MJ ;
RICHARDSON, M ;
TAYLOR, RR .
CORONARY ARTERY DISEASE, 1993, 4 (02) :187-193
[8]   RELEASE OF PLATELET-ACTIVATING FACTOR IN SYSTEMIC LUPUS-ERYTHEMATOSUS [J].
TETTA, C ;
BUSSOLINO, F ;
MODENA, V ;
MONTRUCCHIO, G ;
SEGOLONI, G ;
PESCARMONA, G ;
CAMUSSI, G .
INTERNATIONAL ARCHIVES OF ALLERGY AND APPLIED IMMUNOLOGY, 1990, 91 (03) :244-256
[9]   Identification of the G994→T missense mutation in exon 9 of the plasma platelet-activating factor acetylhydrolase gene as an independent risk factor for coronary artery disease in Japanese men [J].
Yamada, Y ;
Ichihara, S ;
Fujimura, T ;
Yokota, M .
METABOLISM-CLINICAL AND EXPERIMENTAL, 1998, 47 (02) :177-181
[10]   A mutation in plasma platelet-activating factor acetylhydrolase (Val279Phe) is a genetic risk factor for cerebral hemorrhage but not for hypertension [J].
Yoshida, H ;
Imaizumi, T ;
Fujimoto, K ;
Itaya, H ;
Hiramoto, M ;
Yoshimizu, N ;
Fukushi, K ;
Satoh, K .
THROMBOSIS AND HAEMOSTASIS, 1998, 80 (03) :372-375